Adjunctive low-dose naltrexone did not separate from placebo on depressive symptom reduction in a 38-patient randomized trial of adults with moderate major depressive disorder on existing antidepressants.

A narrative review and accompanying expert commentary outlined diagnostic features distinguishing substance-induced psychosis from primary psychotic disorders amid rising cannabis and stimulant exposure.

The Tardive Dyskinesia Impact Scale showed high discrimination and precision across physical function and socioemotional domains in pooled data from 388 patients in the KINECT 3 and KINECT 4 valbenazine trials.

Adjunctive cognitive behavioral therapy reduced depressive symptoms and ideation scores versus treatment as usual in a 93-patient feasibility trial of esketamine for major depression with suicidal ideation.

A JAMA Psychiatry network meta-analysis ranked lumateperone highest for efficacy and aripiprazole highest for acceptability among five FDA-approved adjunctive atypical antipsychotics for major depressive disorder.

A Rhode Island court denied summary judgment in an informed consent suit after a patient developed permanent tardive dyskinesia following an intra-class antipsychotic switch.